



Antibody-Based Therapeutics: Where Are We and Future Perspectives?

Guest Editors:

Prof. Dr. Anthony Rees

Rees Consulting AB, 75591
Uppsala, Sweden

rees@reesconsultingab.com

Dr. Alessandra Micaela Villa

Philochem AG, R&D unit of the
Philogen Group, Otelfingen,
Switzerland

alessandra.villa@philogen.com

Dr. Mattia Matasci

Philochem AG, R&D unit of the
Philogen Group, Otelfingen,
Switzerland

mattia.matasci@philogen.com

Deadline for manuscript
submissions:

closed (30 June 2021)

Message from the Guest Editors

There is a growing interest in the use of immunotherapy approaches for the treatment of cancer, which has been promoted by the clinical results obtained against various types of malignancies using anti-PD-1 and anti-PD-L1 antibodies. The activation of the immune system for a selective removal of tumor cells is the goal of this therapeutic approach, which can be achieved by using two classes of bifunctional products: (i) antibody-based targeted therapeutics (e.g., antibody–cytokine fusions) and (ii) bispecific antibodies. Antibody-based cytokine targeting represents a valuable strategy to increase the therapeutic index of active payloads, such as cytokines. In this Special Issue, we summarise the current state of the art and consider the future perspectives for these therapeutic approaches.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Arne Skerra

Chair of Biological Chemistry,
Technical University of Munich,
Emil-Erlenmeyer-Forum 5, 85354
Freising (Weihenstephan),
Germany

Message from the Editor-in-Chief

Antibodies is a relatively new journal with a major focus on quick dissemination of knowledge related to antibodies, especially how to quickly translate basic research results to therapeutic applications. Because it covers all areas related to antibodies unexpected connections between different areas could be made, leading to major discoveries and opening new fields of research and development. This is enhanced by the large readership of the many antibody-related areas of research. A specific priority area is human monoclonal antibodies for therapy of diseases and aging.

Author Benefits

Open Access:— free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, ESCI (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.8 days after submission; acceptance to publication is undertaken in 3.8 days (median values for papers published in this journal in the second half of 2022).

Contact Us

Antibodies
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibodies
antibodies@mdpi.com
 @Antibodies_MDPI